Chris Freeman - 15 Mar 2026 Form 4 Insider Report for Guardant Health, Inc. (GH)

Reporting relationship: Chief Commercial Officer
Issuer ticker: GH
Reported as of: 15 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Mar 2026, 18:48:14 UTC
Prior SEC filing: 13 Mar 2026
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ John G. Saia, as attorney-in-fact for Chris Freeman

Key filing fact

Chris Freeman filed Form 4 for Guardant Health, Inc. (GH) on 17 Mar 2026.

Key facts

This page summarizes Chris Freeman's Form 4 filing for Guardant Health, Inc. (GH).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Mar 2026, 18:48.

Change

Previous filing in this sequence was filed on 13 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001871615 Primary reporting owner

Freeman Chris

Relationship: Chief Commercial Officer
Address: 3100 HANOVER STREET, PALO ALTO
Signature: /s/ John G. Saia, as attorney-in-fact for Chris Freeman
Signature date: 17 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GH transaction

Common Stock

Options Exercise

Transaction value
Shares: +15,426
Change %: +35%
Price: $0.000000^*
Shares after: 59,296
Date: 15 Mar 2026
Ownership: Direct

GH transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,402
Change %: +2.4%
Price: $0.000000^*
Shares after: 60,698
Date: 15 Mar 2026
Ownership: Direct

GH transaction

Common Stock

Tax liability

Transaction value
Shares: -7,127
Change %: -12%
Price: $85.49^*
Shares after: 53,571
Date: 15 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GH transaction Derivative

Performance-Based Restricted Stock Units

Options Exercise

Transaction value
Shares: -15,426
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,426
Exercise price: $0.000000
Footnotes: F2, F3

GH transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -1,402
Change %: -50%
Price: $0.000000^*
Shares after: 1,402
Date: 15 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,402
Exercise price: $0.000000
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.

Footnote F2

This represents a performance-based restricted stock unit award granted on June 7, 2023 with a 3-year performance metric. The second tranche metric was achieved and the shares vested on March 15, 2026.

Footnote F3

Not applicable for Restricted Stock Units.

Footnote F4

This represents a restricted stock unit award granted on June 9, 2023 that vests over a three-year period. 33% of the shares subject to such award vested on June 15, 2024 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.